August Troendle Sells 15,971 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 15,971 shares of Medpace stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $620.84, for a total value of $9,915,435.64. Following the sale, the chief executive officer directly owned 523,923 shares of the company’s stock, valued at approximately $325,272,355.32. This represents a 2.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Medpace Trading Down 0.2%

Shares of MEDP stock traded down $1.15 during mid-day trading on Thursday, reaching $615.29. The stock had a trading volume of 221,328 shares, compared to its average volume of 333,335. The business’s fifty day moving average is $582.78 and its 200-day moving average is $508.65. The firm has a market cap of $17.17 billion, a price-to-earnings ratio of 36.07, a PEG ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the company posted $3.10 earnings per share. The company’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MEDP. Leerink Partners set a $620.00 price target on Medpace in a research report on Thursday, July 23rd. BMO Capital Markets upped their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Barclays set a $600.00 target price on Medpace in a report on Thursday, July 23rd. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a research report on Monday. Finally, Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $595.20.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Medpace in the 2nd quarter valued at about $1,323,047,000. Wasatch Advisors LP boosted its position in Medpace by 19.4% during the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock worth $371,634,000 after purchasing an additional 125,625 shares in the last quarter. Geode Capital Management LLC grew its holdings in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the period. Renaissance Technologies LLC grew its holdings in Medpace by 8.3% in the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Medpace by 5.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company’s stock valued at $190,044,000 after buying an additional 20,736 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.